All Abstract Submissions Are Currently CLOSED
*Please stay tuned for when we reopen in Fall 2026 for the 2027 program*
The CRS 2026 Annual Meeting and Exposition offers an exceptional opportunity to share your research with an international audience of experts in the design, development, and implementation of novel delivery technologies.
All academic & industry abstracts submitted for the CRS 2026 Annual Meeting & Exposition will go through a rigorous review process to maintain the highest scientific quality of the meeting. All abstracts will be evaluated by the CRS Annual Meeting Program Committee and will be assigned a rank order based on their scientific content.
Technical Session Format
Some abstracts will be selected for oral presentations during regular technical sessions. Each technical session will include invited speakers and several oral presentations that are selected from the submitted abstracts. A moderated discussion will follow at the end of these sessions. There will also be poster presentations available for viewing during the Annual Meeting and Exposition.
Abstracts will be rejected if they do not comply with the minimum submission instructions, do not follow the proper format, and/or do not include all required fields.
Type of Abstract
Explore the different abstract types available for submission to the Annual Meeting. Each option offers a pathway to share your original research or recent innovations with the scientific community by the April 7, 2026, deadline.
- Late-Breaking Abstract Submission: The standard abstract submission is for authors to submit original scientific research for consideration as an oral or poster presentation by the standard deadline of April 7, 2026.
- (NEW!) Late-Breaking Patent Abstract Submission: The patent abstract submission is the primary process for authors to submit recent, original scientific patents for consideration as an oral or poster presentation by the standard deadline of April 7, 2026.
- Local Chapter Abstract Submission: The local chapter abstract submission is only for abstracts selected by the local chapter chairs according to the local chapter proceedings. Prior notification must be made to the AMPC from local chapter representatives before submitting.
Type of Presentation
Late-breaking abstract submissions will be eligible for oral or poster presentations for this year's Annual Meeting & Exposition.
Abstract Fee
Late-breaking abstracts will incur a fee of *$50 USD to be submitted
(*fee is non-refundable)
Submitted Abstracts Must Meet the Following Minimum Requirements:
- Significant and original contribution within the scope of the Controlled Release Society.
- Abstract submitted by the deadline.
- Written in clear English.
- Few or no syntax/spelling mistakes.
- Sufficient data presented, adequately analyzed and discussed with appropriate conclusions supported by the data.
- Meets format guidelines.
Abstract Preparation Checklist:
- Abstract prepared and formatted as outlined in the Preparing for Abstract Submission section of the full Abstract Guidelines here. Abstracts that are not properly prepared and formatted are subject to automatic rejection.
- Abstract (subject to acceptance) will be presented and placed (oral presentation or poster presentation) by the CRS Annual Meeting Program Committee.
- License is granted to the CRS to publish the abstract (subject to acceptance) online.
- Designated presenting author registered for the CRS 2026 Annual Meeting & Exposition and has paid the registration fee.
Abstract Submission:
- Abstract submissions are limited to only (1) submission per person by name, email, and/or institution.
- If accepted, you will be part of the scientific program in the form of either an oral or poster presentation.
- Abstract Submissions for the CRS 2026 Annual Meeting & Exposition will be accepted until April 7, 2026 - 11:59 PM ET.
- Late-breaking abstract submissions will incur a fee of *$50 USD (*fee is non-refundable).
- All authors are expected to review this document prior to submitting.
Process for Abstract Selection:
- Abstracts should contain a substantial portion of unpublished data.
- The criterion for acceptance of presentation at the CRS Annual Meeting & Exposition is based on a peer-review process.
- The authors must obtain any necessary permissions prior to submission of the abstract.
- The AMPC has the right to evaluate, accept, or reject any submitted abstract. The Committee will determine the status (accept or reject) of all submitted abstracts and the presentation format (oral or poster presentation) of all accepted abstracts. The Committee may also switch abstracts to any topic category based on their evaluation and organization requirements.
Abstract Notification:
- Acknowledgement of Late-Breaking submission will be emailed to the presenting author as the primary contact.
- The presenting author will be notified of the abstract status in late April/early May 2026.
- The presenting author must register for the Annual Meeting and pay the registration fee.
- If the presenting author is not registered, the abstract will be withdrawn and will not be included in the Annual Meeting program.
Session Topics and Descriptions for Abstracts
- Alternative Methods to Animal Testing: organs-on-chips, bioreactors, microfl uidic devices, three-dimensional cell assemblies, in vitro recreation of the biological complexity, 3D bioprinting, in vitro/in silico assays to characterize the effi cacy, specifi city, and toxicity of therapeutic agents.
- Artificial Intelligence and Predictive Models: convergence of drug delivery with artifi cial intelligence, machine learning, molecular dynamics, mathematical modeling (PK, PD, compartment modeling), tools for material selection and optimization of pharmacological and biological performance of delivery systems, modeling of biophysical processes (e.g., cell uptake, mass transport, biodistribution, biodegradation, etc.), big data, and OMICs.
- Bioengineering (Focus Group – Bioengineering): bioinspired and biomimetic strategies for the design of drug delivery systems (e.g., cell-mimicking carriers, exosomes, synthetic extracellular vesicles, etc.), construction of biological building blocks, leveraging bio-interactions to create delivery platforms, mimicking the properties of natural particles, and high concentration (nano)biologics.
- Delivery Technologies for Diversified Products: personal and home care areas (cosmetics, skin care, deodorants, antiperspirants, hair care, mouth care, air fresheners, cleaning and sanitizing agents), household products, industrial applications (e.g., paints, coatings, batteries, green energy, etc.), textiles, space applications, sustainable agriculture, nutrition and food systems, aquaculture, and farming.
- Delivery to the Nervous System: systems for delivering therapeutic agents to the central and peripheral nervous system, blood-brain barrier (BBB) and blood-nerve barrier (BNB) crossing, intrathecal, intracranial, intracerebroventricular, and nasal administration, focused ultrasound, and neuro-immunology.
- Gene Delivery and Gene Editing (Focus Group – GDGE): delivery of nucleic acids (e.g., mRNA, pDNA, oligonucleotides, etc.) with nanoformulations, modulation of protein expression, genome editing, vaccination, overcoming biological limitations (e.g., endosomal escape, cellular targeting, biodistribution, etc.).
- Global Health, Special Population, and Women’s Health: solutions for global diseases, diseases affecting developing countries, gender/race-related health with emphasis on women, vulnerable pediatric and geriatric patients, minorities.
- Imaging in Drug Delivery: imaging of drug delivery for monitoring disease progression, biodistribution, nanoparticle kinetics, image-guided drug delivery (e.g., TACE, SIRT, HIFU, etc.), theranostics, companion diagnostics, and image-guided patient stratifi cation.
- Immuno Delivery (Focus Group – ID): targeting immune cells in peripheral tissues and at the sites of immunological reactions, modifi cation of innate and adaptive immunity, immunomodulation of the tumor microenvironment, immunotherapy, microbiome, and neuro-immunology.
- Manufacturing and Process Scale-Up: evaluation and characterization of delivery products, preparation and scale-up, Quality-by-Design (QbD), Quality Control (QC), analytical technologies, Process Analytical Technology (PAT), additive manufacturing, continuous manufacturing, delivery devices, 3D-printing, sustainability, green technologies (e.g., natural, non-modifi ed, renewable materials, etc.), regulatory science, and GMP manufacturing.
- Nanomedicine and Nanoscale Delivery (Focus Group – NND): development, physicochemical and biological characterization, in vivo validation, delivery of therapeutics, functionalization with active-targeting moieties, intracellular and organelle targeting, stromal targeting, microbiome, long-acting formulations, controlled release, injectables, and implantables.
- Ocular Delivery (Focus Group – OcD): drug delivery systems for vision-threatening diseases, drug-device combinations (e.g., contact lenses, punctal plugs, injectables, intravitreal devices, suprachoroidal delivery, and ultrasound-mediated delivery, etc.), overcoming physiological barriers in ocular drug delivery.
- Oral Delivery (Focus Group – OrD): formulation and manufacturing of molecules and biologics to maximize their oral bioavailability, oral delivery of nutraceuticals and food additives, food and beverages as delivery vehicles.
- Skin and Mucosal Delivery (Focus Group – SMD): delivery of therapeutic and diagnostic agents through skin or mucous membranes (e.g., gastrointestinal tract, respiratory tract, other tissues with mucosal lining, etc.), strategies to overcome challenges in topical, subcutaneous, transdermal, intradermal, intramuscular, and mucosal delivery.
All Abstract Submissions Are Currently Closed
*Please stay tuned for when we reopen in Fall 2026 for the 2027 program*
What's next when your abstract is accepted? Click below to find out!
Countdown to Lisbon!
